GLP‑1 Medications & Your Muscles – What Happens to MSK Health When You Lose Weight Fast?
Over the past few months, you’ve likely heard about or know someone who has started taking GLP‑1 agonists. Medications such as Ozempic, Wegovy, Mounjaro, and Zepbound have surged in popularity thanks to their ability to deliver significant weight loss quickly and effectively. But alongside the excitement come important questions, particularly around how such rapid changes may impact your muscles, joints, and overall musculoskeletal (MSK) health.
Rapid weight loss isn’t just fat loss
It is often assumed that when people lose weight quickly, it is purely from fat. However, all weight loss includes a mix of fat and muscle. Research has found that 25–39% of weight lost on GLP‑1 medications comes from muscle mass.
This may leave your clothes feeling looser, but you may also begin to feel weaker.
This doesn’t mean GLP‑1 treatments are “eating your muscle.” These medications greatly reduce appetite, so many people naturally end up eating far fewer calories. When your body isn’t getting enough fuel from food, it starts using stored energy, including some muscle tissue. This is simply the body’s normal response when calorie intake drops quickly.
Is GLP-1 muscle loss bad?
Even though you may lose a small amount of muscle size while taking GLP‑1 medications, studies show these drugs can actually help your muscles work better.
Research suggests GLP‑1 medicines may:
- Reduce extra fat stored inside your muscles
- Help your body use insulin more effectively, which supports muscle health
- Improve the way your muscle fibres behave so they can function more efficiently
MRI studies even show that the muscle changes seen with GLP‑1 medications are healthy adjustments, not signs of muscle damage. Indicating that your muscles are adapting to your new, lower body weight in a normal, healthy way.
So, although a degree of muscle loss can happen, it isn’t severe. It’s just your body adapting naturally as your weight decreases.
Even though GLP‑1 medications can improve muscle quality, losing too much total muscle can still affect how you feel and move in everyday life. It can also impact your long-term health. Here’s why it matters:
- Higher Risk of Falls: Your muscles help keep you steady and balanced. When you lose muscle, your balance can be affected, leading to falls.
- Slower Metabolism: Muscle burns more calories at rest than fat does. So, when muscle decreases, your resting metabolism naturally slows down, which can make maintaining weight loss harder.
- Faster Age-Related Muscle Loss: As we get older, we naturally lose about 1–2% of our muscle each year, and losing weight quickly can accelerate that process.
Supporting weight loss without compromising strength
This is where DocHQ plays a critical role. By providing timely access (<48h) to Chartered Physiotherapists, DocHQ ensures employees can seek guidance early, adapt safely and stay active throughout periods of rapid change. Rehabilitation and strengthening programmes are continuously adjusted in real time, responding to symptoms, progress and engagement to reduce the likelihood of injury before it occurs.
With clinically governed pathways and full data visibility, organisations gain reassurance that musculoskeletal health is being proactively managed – not reactively treated after absence begins.
The opportunity for employers is clear: support the health benefits of weight loss while safeguarding the strength, resilience and mobility that underpin a productive workforce.
References
Prado, C.M., Phillips, S.M., Gonzalez, M.C. & Heymsfield, S.B., 2024. Muscle matters: the effects of medically induced weight loss on skeletal muscle. The Lancet Diabetes & Endocrinology, Volume 12, Issue 11, pp. 785–787.
Gatto, A., Liu, K., Milan, N. & Wong, S., 2025. The Effects of GLP‑1 Agonists on Musculoskeletal Health and Orthopedic Care. Current Reviews in Musculoskeletal Medicine, 18, pp. 469–480.
Linge, J., Birkenfeld, A.L. & Neeland, I.J. (2024) Muscle Mass and Glucagon‑Like Peptide‑1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation, 15 October 2024. Available at: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.124.067676
